A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501).
Publication
, Journal Article
Morrison, VA; Jung, S; Johnson, JL; Leonard, J; Cheson, BD
Published in: Journal of Clinical Oncology
May 20, 2011
Duke Scholars
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2011
Volume
29
Issue
15_suppl
Start / End Page
TPS223 / TPS223
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Morrison, V. A., Jung, S., Johnson, J. L., Leonard, J., & Cheson, B. D. (2011). A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501). Journal of Clinical Oncology, 29(15_suppl), TPS223–TPS223. https://doi.org/10.1200/jco.2011.29.15_suppl.tps223
Morrison, V. A., S. Jung, J. L. Johnson, J. Leonard, and B. D. Cheson. “A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501).” Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): TPS223–TPS223. https://doi.org/10.1200/jco.2011.29.15_suppl.tps223.
Morrison VA, Jung S, Johnson JL, Leonard J, Cheson BD. A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501). Journal of Clinical Oncology. 2011 May 20;29(15_suppl):TPS223–TPS223.
Morrison, V. A., et al. “A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501).” Journal of Clinical Oncology, vol. 29, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2011, pp. TPS223–TPS223. Crossref, doi:10.1200/jco.2011.29.15_suppl.tps223.
Morrison VA, Jung S, Johnson JL, Leonard J, Cheson BD. A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011 May 20;29(15_suppl):TPS223–TPS223.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2011
Volume
29
Issue
15_suppl
Start / End Page
TPS223 / TPS223
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences